Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

235 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients.
Pri-Paz Basson Y, Tayer-Shifman OE, Naser R, Tartakover Matalon S, Kimhi O, Gepstein R, Halperin T, Ziv-Baran T, Ziv A, Parikh R, Kivity S, Levy Y. Pri-Paz Basson Y, et al. Among authors: ziv a, ziv baran t. Clin Rheumatol. 2022 Dec;41(12):3879-3885. doi: 10.1007/s10067-022-06348-z. Epub 2022 Sep 2. Clin Rheumatol. 2022. PMID: 36050514 Free PMC article.
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
Heshin-Bekenstein M, Ziv A, Toplak N, Hagin D, Kadishevich D, Butbul YA, Saiag E, Kaufman A, Shefer G, Sharon O, Pel S, Elkayam O, Uziel Y. Heshin-Bekenstein M, et al. Among authors: ziv a. Rheumatology (Oxford). 2022 Nov 2;61(11):4263-4272. doi: 10.1093/rheumatology/keac103. Rheumatology (Oxford). 2022. PMID: 35179569 Free PMC article.
Correction to: Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients.
Pri-Paz Basson Y, Tayer-Shifman OE, Naser R, Tartakover Matalon S, Kimhi O, Gepstein R, Halperin T, Ziv-Baran T, Ziv A, Parikh R, Kivity S, Levy Y. Pri-Paz Basson Y, et al. Among authors: ziv a, ziv baran t. Clin Rheumatol. 2022 Dec;41(12):3925. doi: 10.1007/s10067-022-06412-8. Clin Rheumatol. 2022. PMID: 36251175 Free PMC article. No abstract available.
Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study.
Heshin-Bekenstein M, Ziv A, Toplak N, Lazauskas S, Kadishevich D, Ben-Nun Yaari E, Miller-Barmak A, Butbul Aviel Y, Saiag E, Pel S, Elkayam O, Uziel Y, Furer V. Heshin-Bekenstein M, et al. Among authors: ziv a. Vaccines (Basel). 2023 Apr 10;11(4):819. doi: 10.3390/vaccines11040819. Vaccines (Basel). 2023. PMID: 37112731 Free PMC article.
Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study.
Eviatar T, Ziv A, Oved A, Miller-Barmak A, Pappo A, Livny R, Amarilyo G, Aviel YB, Naor R, Pel S, Furer V, Elkayam O, Uziel Y, Heshin-Bekenstein M. Eviatar T, et al. Among authors: ziv a. Vaccine. 2024 Dec 2;42(26):126426. doi: 10.1016/j.vaccine.2024.126426. Epub 2024 Oct 17. Vaccine. 2024. PMID: 39423454
Vaccinology in pediatric rheumatology: Past, present and future.
Bizjak M, Heshin-Bekenstein M, Jansen MHA, Ziv A, Angevare S, Uziel Y, Wulffraat NM, Toplak N; PReS Vaccination Working Party. Bizjak M, et al. Among authors: ziv a. Front Pediatr. 2023 Jan 10;10:1098332. doi: 10.3389/fped.2022.1098332. eCollection 2022. Front Pediatr. 2023. PMID: 36704144 Free PMC article. Review.
235 results